Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells

Cell Biology International

Volumn 35, Issue 3, 2011, Pages 235-248

  Müller, Maike ^a   Raabe, Oksana ^b   Addicks, Klaus ^a   Wenisch, Sabine ^b   Arnhold, Stefan ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cell viability; Differentiation; Mesenchymal stem cell; Migration; NSAID; Tendinopathy

Indexed keywords

CELECOXIB; FLUNIXIN; FLUNIXIN MEGLUMINE; MELOXICAM; PHENYLBUTAZONE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL KINETICS; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORSE; MALE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST;

AGGRECANS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CLONIXIN; COLLAGEN TYPE II; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; HORSES; MALE; MESENCHYMAL STEM CELLS; PHENYLBUTAZONE; PYRAZOLES; SULFONAMIDES; THIAZINES; THIAZOLES;

EQUIDAE;

EID: 79957617715     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090211     Document Type: Article

References (45)

1. Assmus B, Tonn T, Seeger FH, Yoon C-H, Leistner D, Klotsche J, Schächinger V, Seifried R, Zeiher AM, Dimmeler S. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010;55:1385-94.
2. Baller LS, Hendrickson DA. Management of equine orthopedic pain. Vet Clin North Am Equine Pract 2002;18:117-31.
3. Baxter GM. Instrumentation and techniques for treating orthopedic infections in horses. Vet Clin North Am Equine Pract 1996;12:303-35.
4. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992;102:341-51.
5. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res 2005;52:302-6.
6. Blois SL, Allen DG, Wood RD, Conlon PD. Effects of aspirin, caprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res 2010;71:349-58.
7. Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1990;39:86-109.
8. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001;7:259-64.
9. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007;58:239-52.
10. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-49.
11. Chang JK, Li CJ, Wu SC, Yeh CH, Chen CH, Fu YC, Wang GJ, Ho ML. Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells. Biochem Pharmacol 2007;74:1371-82.
12. Chang JK, Wang GJ, Tsai ST, Ho ML. Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res 2005;46:200-10.
13. Chen JL, Hunt P, McElvain M, Black T, Kaufman S, Choi ES. Osteoblast precursor cells are found in CD34+ cells from human bone marrow. Stem Cells 1997;15:368-77.
14. Clemett D, Goa KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
15. Crovace A, Lacitignola L, De Siena R, Rossi G, Francioso E. Cell therapy for tendon repair in horses: an experimental study. Vet Res Commun 2007;31 Suppl 1:281-3.
16. Del Bue M, Ricco S, Conti V, Merli E, Ramoni R, Grolli S. Platelet lysate promotes in vitro proliferation of equine mesenchymal stem cells and tenocytes. Vet Res Comm 2007;31:289-92.
17. Depre M, Ehrich E, Van Hecken A, De L, I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000;56:167-74.
18. Evans CE, Butcher C. The influence on human osteoblasts in vitro of non-steroidal anti-inflammatory drugs which act on different cyclooxygenase enzymes. J Bone Joint Surg Br 2004;86:444-9.
19. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res 2009;27:1675-80.
20. Gerson SL. Mesenchymal stem cells: no longer second class marrow citizens. Nat Med 1999;5:262-4.
21. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002;20:1164-9.
22. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review. Vet J 2006;171:51-69.
23. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
24. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol 1999;58:983-90.
25. Ho ML, Chang JK, Wang GJ. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop Relat Res 1995;270-8.
26. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996;97:1732-40.
27. Justesen J, Stenderup K, Eriksen EF, Kassem M. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif Tissue Int 2002;71:36-44.
28. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995;36-46.
29. Kellinsalmi M, Parikka V, Risteli J, Hentunen T, Leskela HV, Lehtonen S, Selander K, Vaananen K, Lehenkari P. Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro. Eur J Pharmacol 2007;572:102-10.
30. Korkmaz Y, Bloch W, Steinritz D, Baumann MA, Addicks K, Schneider K, Raab WH. Bradykinin mediates phosphorylation of eNOS in odontoblasts. J Dent Res 2006;85:536-41.
31. Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 2000;102:2124-30.
32. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-74.
33. Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K. Effects of celecoxib on human chondrocytes-enhanced production of chemokines. Clin Exp Rheumatol 2007;25:11-16.
34. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998;13:371-82.
35. Ouyang HW, Goh JC, Lee EH. Use of bone marrow stromal cells for tendon graft-to-bone healing: histological and immunohistochemical studies in a rabbit model. Am J Sports Med 2004;32:321-7.
36. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
37. Prokopi M, Pula G, Mayr U, Devue C, Gallaghaer J, Xiao Q, Boulanger CM, Westwood N, Urbich C, Willeit J, et al. Proteomic analysis reveals presence of platelet microparticles in endothlial progenitor cell cultures. Blood 2009;16:723-32.
38. Smith RK. Mesenchymal stem cell therapy for equine tendinopathy. Disabil Rehabil 2008;30:1752-8.
39. Smith RK, Korda M, Blunn GW, Goodship AE. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J 2003;35:99-102.
40. Tsai WC, Hsu CC, Chou SW, Chung CY, Chen J, Pang JH. Effects of celecoxib on migration, proliferation and collagen expression of tendon cells. Connect Tissue Res 2007;48:46-51.
41. Tsai WC, Tang FT, Hsu CC, Hsu YH, Pang JH, Shiue CC. Ibuprofen inhibition of tendon cell proliferation and upregulation of the cyclin kinase inhibitor p21CIP1. J Orthop Res 2004;22:586-91.
42. Ueno K, Haba T, Woodbury D, Price P, Anderson R, Jee WS. The effects of prostaglandin E2 in rapidly growing rats: depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. Bone 1985;6:79-86.
43. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
44. Wang Y, Chen X, Zhu W, Zhang H, Hu S, Cong X. Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 2006;33:696-701.
45. Zhang X, Yang M, Lin L, Chen P, Ma KT, Zhou CY, Ao YF. Runx2 overexpression enhances osteoblastic differentiation and mineralization in adipose-derived stem cells in vitro and in vivo. Calcif Tissue Int 2006;79:169-78.